Position in DMAC
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$288,723
New position
Shares Held
41,012
first reported quarter
Ownership
0.076%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#31
of 87 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Ballentine Partners, LLC holds $12,066,429 across 29 Biotechnology names. DMAC ranks #13 (2.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,245 | $2,605,347 | |
| 2 | KRYS |
Krystal Biotech, Inc.
|
2,138 | $794,629 | |
| 3 | ARGX |
Argenx SE
|
772 | $716,237 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,054 | $657,210 | |
| 5 | INCY |
Incyte Corp
|
4,816 | $545,940 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,695 | $510,244 | |
| 7 | RPRX |
Royalty Pharma plc
|
9,027 | $506,143 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
6,331 | $495,526 |
All Filings in DMAC
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $288,723 | 41,012 | Shares | Other | 2026-07-17 | |
| No filing history on record for this holder in this stock. | ||||||